Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Active not recruiting × mCRPC × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 101 Carcinoma, Non-Small-Cell Lung 86 Prostatic Neoplasms 51 Multiple Myeloma 43 Neoplasms 33 Neoplasm Metastasis 30 Ovarian Neoplasms 24 Melanoma 22 Parkinson Disease 4, Autosomal Dominant Lewy Body 21 Urinary Bladder Neoplasms 20 Recurrence 19 Leukemia, Lymphocytic, Chronic, B-Cell 19 Carcinoma, Renal Cell 19 Lung Neoplasms 18 Colorectal Neoplasms 18 Triple Negative Breast Neoplasms 17 Carcinoma, Hepatocellular 17 Leukemia, Myeloid, Acute 16 Stomach Neoplasms 14 Nasopharyngeal Carcinoma 14 Lymphoma, Non-Hodgkin 14 Lymphoma, Large B-Cell, Diffuse 13 Lymphoma 12 Colonic Neoplasms 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Fallopian Tube Neoplasms 11 Carcinoma 11 Squamous Cell Carcinoma of Head and Neck 10 Papillomavirus Infections 10 Endometrial Neoplasms 10

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡